Patents matching “formulation”

WO 2026106858

FORMULATIONS ET PROCÉDÉS POUR MAINTENIR UNE SUSPENSION ET UNE VIABILITÉ DE CELLULES

BAYER HEALTHCARE LLC [US] · Granted May 21, 2026 · Expires May 16, 2046

WO 2026087531

FORMULATIONS DE CLASCOTÉRONE ET LEURS MÉTHODES D'UTILISATION

CASSIOPEA S P A [IT] · Granted Apr 30, 2026 · Expires Apr 25, 2046

US 20260108463

NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION

BIOFRONTERA BIOSCIENCE GMBH [DE] · Granted Apr 23, 2026 · Expires Apr 18, 2046

US 20260027049

AVACOPAN FORMULATIONS

AMGEN INC [US] · Granted Jan 29, 2026 · Expires Jan 24, 2046

WO 2026010917

FORMULATIONS NUTRITIONNELLES PERMETTANT DE MAINTENIR DES MICROBIOTE ET FONCTION INTESTINAUX SAINS

ABBOTT LAB [US] · Granted Jan 8, 2026 · Expires Jan 3, 2046

WO 2026008525

FORMULATIONS STABLES CONTENANT DES RADIONUCLÉIDES

BAYER AG [DE] · Granted Jan 8, 2026 · Expires Jan 3, 2046

WO 2025242583

NOUVELLE FORMULATION COMPRENANT DE L'ÉLINZANÉTANT DANS UNE DISPERSION SOLIDE

BAYER CONSUMER CARE AG [CH] · Granted Nov 27, 2025 · Expires Nov 22, 2045

WO 2025242584

FORMULATION DE CAPSULE DE GÉLATINE MOLLE STABLE POUR ÉLINZANÉTANT

BAYER CONSUMER CARE AG [CH] · Granted Nov 27, 2025 · Expires Nov 22, 2045

US 12419831

Hydrocortisone oral liquid formulations

Eton Pharmaceuticals, Inc. · Granted Sep 23, 2025 · Expires Sep 18, 2045

US 12419958

Clinical formulations

Astellas Institute for Regenerative Medicine · Granted Sep 23, 2025 · Expires Sep 18, 2045

WO 2025186043

FORMULATION PHARMACEUTIQUE POUR ANTICORPS ANTI-CCR8

BAYER AG [DE] · Granted Sep 12, 2025 · Expires Sep 7, 2045

US 12403183

Factor VIII polypeptide formulations

BIOVERATIV THERAPEUTICS INC. · Granted Sep 2, 2025 · Expires Aug 28, 2045

US 12403164

Lentiviral vector formulations

BIOVERATIV THERAPEUTICS INC. · Granted Sep 2, 2025 · Expires Aug 28, 2045

US 12390419

Formulations of (R)-2-amino-3-phenylpropyl carbamate

AXSOME MALTA LTD. · Granted Aug 19, 2025 · Expires Aug 14, 2045

US 12383516

Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent

Amphastar Pharmaceuticals, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

US 12383522

Baclofen formulations and methods of minimizing patient exposure to metabolite variations

AMNEAL PHARMACEUTICALS LLC · Granted Aug 12, 2025 · Expires Aug 7, 2045

US 12370188

Formulations of dazucorilant, a glucocorticoid receptor modulator

Corcept Therapeutics Incorporated · Granted Jul 29, 2025 · Expires Jul 24, 2045

US 12370241

Nasal powder formulation for treatment of hypoglycemia

Amphastar Pharmaceuticals, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

US 12364685

Isoxazoline parasiticide formulations

Tarsus Pharmaceuticals, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

US 12357582

Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Jul 15, 2025 · Expires Jul 10, 2045

US 12357604

Topical formulations of cannabinoids and use thereof in the treatment of pain

INMED PHARMACEUTICALS INC. · Granted Jul 15, 2025 · Expires Jul 10, 2045

US 12357623

Method for treating a disease or condition using a pyrazole compound or formulation thereof

Rigel Pharmaceuticals, Inc. · Granted Jul 15, 2025 · Expires Jul 10, 2045

US 12350322

Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunotherapy of diseases impacted by IL-6 dysregulation

United Biomedical, Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

US 12343350

Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

Windtree Therapeutics, Inc. · Granted Jul 1, 2025 · Expires Jun 26, 2045